Industry news that matters to you.  Learn more

U of T Researchers Unlock Clues to Thyroid Cancer

Researchers at the University of Toronto and Mount Sinai Hospital have utilized proteomic technologies to discover proteins secreted by thyroid cancer cell lines to identify and characterize potential biomarkers for the future management of thyroid carcinomas.

New Cervical Cancer Test Beats Pap Smear-study

A new way to test for cervical cancer is more accurate than a pap smear and identified more dangerous lesions, an Italian study showed on Tuesday.

Researchers used the traditional test for the human papilloma virus that causes cervical cancer and combined it with another that indicated specific cancer-causing activity in cells, said Guglielmo Ronco, a cancer epidemiologist at the Centre for Cancer Prevention in Turin, who led the study.

A simple test for a protein called P16INK4A provided a biomarker showing cell changes that indicated a woman likely has pre-cancerous lesions, Ronco and colleagues reported in the journal Lancet Oncology.

Epigenomics and Predictive Biosciences Extend Licensing Deal for Prostate Cancer Test

Epigenomics AG, the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced that they have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009. Under the terms of the original agreement, Predictive Biosciences had obtained rights to develop a prostate cancer test incorporating this well known DNA methylation biomarker and an option to license GSTP1 for commercialization of this test as a laboratory service in the United States. Based on strong continued progress in developing the test, Predictive Biosciences has now executed this option, triggering an undisclosed one-time license fee to Epigenomics. Epigenomics will also be entitled to royalties on future sales generated with Predictive Biosciences’ prostate cancer test, which is still in development.

Personalized Medicines Are Shaping the Way R&D Is Done, According to Tufts Center for the Study of Drug Development

Personalized medicine development, occupying a growing role in the clinical pipelines of drug developers, is leading companies to change their R&D paradigms, including how they make go/no-go decisions, according to a recently completed study by the Tufts Center for the Study of Drug Development.

New Multiplex Tissue Biomarker Service Launched to Advance Companion Diagnostics Development in a Regulated Environment

Flagship Biosciences announced today the launch of a new tissue biomarker multiplexing analytical tool for tumors and other tissues. The patent pending technique is based on advanced image registration approaches in radiology fields and applied to consecutive histology sections. The novel technology approach will be presented at Pathology Visions 2010 in San Diego. Flagship is currently offering the multiplexing technology as part of their digital pathology services.